Ticker Details
Protagonist Therapeutics, Inc. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
IPO Date:	August 11, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$6.38B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.63 | 2.80%
Avg Daily Range (30 D):	$2.04 | 2.01%
Avg Daily Range (90 D):	$1.94 | 2.06%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	.42M
Avg Daily Volume (90 D):	.53M

Trade Size
Avg Trade Size (Sh.):	71
Avg Trade Size (Sh.) (30 D):	42
Avg Trade Size (Sh.) (90 D):	44

Institutional Trades
Total Institutional Trades:	3,324
Avg Institutional Trade:	$3.44M
Avg Institutional Trade (30 D):	$8.45M
Avg Institutional Trade (90 D):	$8.06M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.25M
Avg Closing Trade (30 D):	$13.92M
Avg Closing Trade (90 D):	$14.59M
Avg Closing Volume:	149.26K

News

Apr 22, 2026 @ 5:00 PM Polycythemia Vera Market Set for Transformation: K... Source: Delveinsight

Apr 2, 2026 @ 10:14 AM This Healthcare Stock Barely Flinches During Marke... Source: James Halley

Mar 19, 2026 @ 12:25 PM Johnson & Johnson-Protagonist Therapeutics Partner... Source: Vandana Singh

Feb 25, 2026 @ 8:28 PM Protagonist Stock Up 120%, but One Fund Just Revea... Source: Jonathan Ponciano

Oct 23, 2025 @ 6:25 PM Moody Aldrich Dumps Entire Stake in Chart Industri... Source: Adam Palasciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.81	$.06	$-.7
Diluted EPS	$-1.82	$.05	$-.7
Revenue	$74.06M	$56.37M	$7.44M
Gross Profit
Net Income / Loss	$-114.71M	$3.78M	$-44.38M
Operating Income / Loss	$-142.47M	$-3.65M	$-50.36M
Cost of Revenue
Net Cash Flow	$54.12M	$65.32M	$14.68M
PE Ratio